Karyopharm Therapeutics (NASDAQ:KPTI) Stock Rating Lowered by Robert W. Baird

Karyopharm Therapeutics (NASDAQ:KPTI) was downgraded by investment analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating in a research note issued to investors on Friday. They presently have a $3.00 price target on the stock. Robert W. Baird’s price objective indicates a potential downside of 57.20% from the company’s current price.

A number of other research analysts have also recently issued reports on KPTI. Royal Bank Of Canada reissued an “outperform” rating and issued a $16.00 target price on shares of Karyopharm Therapeutics in a research note on Tuesday, July 21st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Karyopharm Therapeutics in a research report on Tuesday, June 9th. HC Wainwright lowered Karyopharm Therapeutics from a “buy” rating to a “negative” rating in a report on Friday. Weiss Ratings cut Karyopharm Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Finally, Piper Sandler reiterated an “overweight” rating and issued a $16.00 price objective (up from $8.00) on shares of Karyopharm Therapeutics in a report on Monday, April 27th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $13.00.

Karyopharm Therapeutics Trading Up 2.2%

Shares of KPTI opened at $7.01 on Friday. The stock has a market cap of $158.85 million, a P/E ratio of -0.46 and a beta of 0.80. The stock’s 50-day moving average price is $9.00 and its two-hundred day moving average price is $8.23. Karyopharm Therapeutics has a 1 year low of $3.65 and a 1 year high of $10.99.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($1.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.21. The firm had revenue of $35.07 million for the quarter, compared to analyst estimates of $31.40 million. As a group, equities analysts forecast that Karyopharm Therapeutics will post -3.24 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Baird Financial Group Inc. acquired a new position in shares of Karyopharm Therapeutics during the 2nd quarter worth approximately $45,000. XTX Topco Ltd acquired a new stake in shares of Karyopharm Therapeutics in the 2nd quarter valued at approximately $56,000. Hsbc Holdings PLC acquired a new stake in shares of Karyopharm Therapeutics in the 1st quarter valued at approximately $66,000. Corient Private Wealth LLC bought a new position in shares of Karyopharm Therapeutics in the fourth quarter valued at $74,000. Finally, Tudor Investment Corp ET AL acquired a new position in Karyopharm Therapeutics during the fourth quarter worth $95,000. 66.44% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Karyopharm Therapeutics

Here are the key news stories impacting Karyopharm Therapeutics this week:

• Positive Sentiment: Karyopharm plans to submit a supplemental New Drug Application in August 2026 for selinexor plus ruxolitinib in myelofibrosis under the FDA’s accelerated-approval pathway. The company will request priority review, and approval could make the treatment the first approved combination therapy for myelofibrosis. Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
• Neutral Sentiment: The company said the XPORT-EC-042 trial showed a 5.3-month median progression-free-survival advantage for selinexor in the modified intent-to-treat population, but it plans to continue monitoring patients for longer-term outcomes rather than seek an immediate endometrial-cancer expansion.
• Negative Sentiment: The Phase 3 XPORT-EC-042 trial failed to meet its primary progression-free-survival endpoint. Karyopharm is reducing planned investment in endometrial cancer and redirecting resources toward its myelofibrosis and multiple myeloma programs, removing a potential growth driver. Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer
• Negative Sentiment: HC Wainwright reaffirmed its neutral rating but cut its price target to $3 from $13, signaling substantially lower expectations following the trial setback. Benzinga
• Negative Sentiment: The failed trial triggered intense trading volatility and a temporary news-pending halt. Pomerantz also announced an investigation into potential investor claims, adding legal overhang. Pomerantz Investor Alert
• Neutral Sentiment: Executive Vice President Stuart Poulton sold 189 shares for approximately $1,342, a small reduction of his holdings that is unlikely to materially affect the investment case.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.